Company intelligence / Profile preview
Tarsa Therapeutics, Inc.
Philadelphia, Pennsylvania, United Statestarsatherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
Completed Phase 3 ORACAL trial for TBRIA (oral calcitonin) which met its primary endpoint and demonstrated statistical superiority to both placebo and nasal calcitonin spray in increasing bone mineral density at the lumbar spine after 48 weeks of use.
- Therapeutic areas
- EndocrinologyRheumatology
- Modalities
- Small moleculeRecombinant protein (oral calcitonin)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
R-Pharm JSC
Beyond the preview
Go deeper on Tarsa Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tarsa Therapeutics, Inc..